Literature DB >> 18698321

Potential adverse effects of amphetamine treatment on brain and behavior: a review.

S M Berman1, R Kuczenski, J T McCracken, E D London.   

Abstract

Amphetamine stimulants have been used medically since early in the twentieth century, but they have a high abuse potential and can be neurotoxic. Although they have long been used effectively to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents, amphetamines are now being prescribed increasingly as maintenance therapy for ADHD and narcolepsy in adults, considerably extending the period of potential exposure. Effects of prolonged stimulant treatment have not been fully explored, and understanding such effects is a research priority. Because the pharmacokinetics of amphetamines differ between children and adults, reevaluation of the potential for adverse effects of chronic treatment of adults is essential. Despite information on the effects of stimulants in laboratory animals, profound species differences in susceptibility to stimulant-induced neurotoxicity underscore the need for systematic studies of prolonged human exposure. Early amphetamine treatment has been linked to slowing in height and weight growth in some children. Because the number of prescriptions for amphetamines has increased several fold over the past decade, an amphetamine-containing formulation is the most commonly prescribed stimulant in North America, and it is noteworthy that amphetamines are also the most abused prescription medications. Although early treatment does not increase risk for substance abuse, few studies have tracked the compliance and usage profiles of individuals who began amphetamine treatment as adults. Overall, there is concern about risk for slowed growth in young patients who are dosed continuously, and for substance abuse in patients first medicated in late adolescence or adulthood. Although most adult patients also use amphetamines effectively and safely, occasional case reports indicate that prescription use can produce marked psychological adverse events, including stimulant-induced psychosis. Assessments of central toxicity and adverse psychological effects during late adulthood and senescence of adults who receive prolonged courses of amphetamine treatment are warranted. Finally, identification of the biological factors that confer risk and those that offer protection is also needed to better specify the parameters of safe, long-term, therapeutic administration of amphetamines to adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698321      PMCID: PMC2670101          DOI: 10.1038/mp.2008.90

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  202 in total

1.  Lisdexamfetamine dimesylate: the first prodrug stimulant.

Authors:  David W Goodman
Journal:  Psychiatry (Edgmont)       Date:  2007-08

Review 2.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  Genetic and environmental influences on drug use and abuse/dependence in male and female twins.

Authors:  M B van den Bree; E O Johnson; M C Neale; R W Pickens
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

4.  Stimulant drug treatment of hyperactivity: biochemical correlates.

Authors:  J Elia; B G Borcherding; W Z Potter; I N Mefford; J L Rapoport; C S Keysor
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

5.  Amphetamine metabolism in amphetamine psychosis.

Authors:  E Anggård; L E Jönsson; A L Hogmark; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

Review 6.  The dopamine transporter and attention-deficit/hyperactivity disorder.

Authors:  Bertha K Madras; Gregory M Miller; Alan J Fischman
Journal:  Biol Psychiatry       Date:  2005-01-05       Impact factor: 13.382

7.  Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile.

Authors:  D S Segal; R Kuczenski
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

8.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

Review 9.  Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.

Authors:  L S Goldman; M Genel; R J Bezman; P J Slanetz
Journal:  JAMA       Date:  1998-04-08       Impact factor: 56.272

10.  Psychostimulants for secondary depression in medical illness.

Authors:  P Masand; P Pickett; G B Murray
Journal:  Psychosomatics       Date:  1991       Impact factor: 2.386

View more
  67 in total

1.  Adolescent rat circadian activity is modulated by psychostimulants.

Authors:  M Bergheim; P B Yang; K D Burau; N Dafny
Journal:  Brain Res       Date:  2011-10-19       Impact factor: 3.252

2.  Neuronal development genes are key elements mediating the reinforcing effects of methamphetamine, amphetamine, and methylphenidate.

Authors:  Ike Dela Peña; Se Jin Jeon; Eunyoung Lee; Jong Hoon Ryu; Chan Young Shin; Minsoo Noh; Jae Hoon Cheong
Journal:  Psychopharmacology (Berl)       Date:  2013-06-20       Impact factor: 4.530

Review 3.  Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies.

Authors:  Thomas J Spencer; Ariel Brown; Larry J Seidman; Eve M Valera; Nikos Makris; Alexandra Lomedico; Stephen V Faraone; Joseph Biederman
Journal:  J Clin Psychiatry       Date:  2013-09       Impact factor: 4.384

4.  Adolescent Δ9-Tetrahydrocannabinol Exposure and Astrocyte-Specific Genetic Vulnerability Converge on Nuclear Factor-κB-Cyclooxygenase-2 Signaling to Impair Memory in Adulthood.

Authors:  Yan Jouroukhin; Xiaolei Zhu; Alexey V Shevelkin; Yuto Hasegawa; Bagrat Abazyan; Atsushi Saito; Jonathan Pevsner; Atsushi Kamiya; Mikhail V Pletnikov
Journal:  Biol Psychiatry       Date:  2018-08-16       Impact factor: 13.382

5.  Methylphenidate and Guanfacine Ameliorate ADHD-Like Phenotypes in Fez1-Deficient Mice.

Authors:  Akiko Sumitomo; Ayumi Saka; Keisho Ueta; Kouta Horike; Kazuko Hirai; Nao J Gamo; Takatoshi Hikida; Keiichi I Nakayama; Akira Sawa; Takeshi Sakurai; Toshifumi Tomoda
Journal:  Mol Neuropsychiatry       Date:  2018-04-26

6.  Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.

Authors:  Joshua A Lile; Shanna Babalonis; Cleeve Emurian; Catherine A Martin; Daniel P Wermeling; Thomas H Kelly
Journal:  J Clin Pharmacol       Date:  2010-07-29       Impact factor: 3.126

7.  D-Amphetamine Exposure Differentially Disrupts Signaling Across Ontogeny in the Zebrafish.

Authors:  Bradley J Serpa; Jennifer D Bullard; Victoria C Mendiola; Crystal J Smith; Brandon Stewart; Lisa R Ganser
Journal:  Bioelectricity       Date:  2019-06-14

8.  The effects of amphetamine injections on feeding behavior and the brain expression of orexin, CART, tyrosine hydroxylase (TH) and thyrotropin releasing hormone (TRH) in goldfish (Carassius auratus).

Authors:  Hélène Volkoff
Journal:  Fish Physiol Biochem       Date:  2012-12-11       Impact factor: 2.794

9.  Effects of self-administered methamphetamine on discrimination learning and reversal in nonhuman primates.

Authors:  Brian D Kangas; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-02       Impact factor: 4.530

10.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.